Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
704 studies found for:    Open Studies | "Lymphoma, Non-Hodgkin"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Procedure: Stem cell infusion;   Procedure: TLI;   Drug: Anti-thymocyte globulin;   Drug: Solumedrol;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
2 Recruiting A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Vincristine;   Drug: Idarubicin;   Drug: Dexamethasone
3 Recruiting Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Rituximab;   Drug: Lenalidomide;   Drug: Placebo
4 Not yet recruiting A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: TAK-659;   Drug: Bendamustine;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Lenalidomide;   Drug: Ibrutinib
5 Recruiting BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Busulfan;   Drug: Etoposide;   Drug: Bendamustine
6 Recruiting Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: ABP 798;   Drug: Rituximab
7 Recruiting Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Copanlisib (BAY 80-6946);   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Bendamustine;   Drug: Prednisone
8 Recruiting A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: LAM-002A
9 Recruiting Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BAY1862864
10 Recruiting A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: CC-122
11 Recruiting GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Obinutuzumab and Pixantrone
12 Not yet recruiting Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Cytokine-induced killer cells (CIK)
13 Recruiting ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: ESHAP-Imatinib
14 Recruiting Phase III Copanlisib in Rituximab-refractory iNHL
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: BAY No. 80 6946;   Drug: Placebo
15 Recruiting BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BI 836826
16 Not yet recruiting Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin's
Interventions: Drug: Obinutuzumab;   Drug: Gemcitabine;   Drug: Dexamethasone;   Drug: Cisplatin
17 Recruiting Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Condition: Lymphoma,Non-Hodgkin
Interventions: Drug: Copanlisib (BAY 80-6946);   Drug: Placebo;   Drug: Rituximab
18 Recruiting A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non Hodgkin
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Obinutuzumab;   Drug: Polatuzumab Vedotin;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Rituximab
19 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
20 Recruiting Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma
Condition: Lymphoma, Non-Hodgkin;Hodgkin Disease
Interventions: Drug: R-CHOP/CHOPE or ABVD chemotherapy regimen;   Drug: R-CDOP/CDOPE or DBVD chemotherapy regimen

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.